Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st April, 2023 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and year ending 31st March, 2023, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
31-03-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company has received intimation from shareholder of the Company, regarding loss of share certificate(s) as details mentioned below. An email request received from Shareholder is enclosed herewith.
18-03-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
09-03-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
09-03-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
09-03-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - SBO Change - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

 This is to inform you that the Board of Directors of the Company have been informed by our Promoter Group entity - Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust), that the Significant Beneficial Owner (SBO) Mr. Subba Rao Jasti, father of Shri Venkateswarlu Jasti, Managing Director of our company has passed away on 2nd February 2023. In terms of the WILL executed by Mr. Subba Rao Jasti, the 9,980 equity shares held by him in the said promoter group entity devolved and transmitted to Mrs. Sudharani Jasti on 08th March 2023, one of the promoter of our company. Post this transmission Mrs. Sudharani Jasti becomes SBO of the listed entity. The changes in the particulars relating to SBO will accordingly be updated in the next shareholding pattern to be filed for the quarter ended 31st March, 2023 in terms of LODR Regulations as amended. This intimation is also being uploaded on the Company's website at www.suvenpharm.com
08-03-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and nine months ended December 31, 2022 conducted after the meeting of Board of Directors held on February 6, 2023. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
13-02-2023

Suven Pharmaceuticals Results Earnings Call for Q3FY23

 Conference Call with Suven Pharmaceuticals Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
08-02-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated January 31, 2023, that audio recording of the conference call for the quarter and nine months ended December 31, 2022 held on Tuesday, February 7, 2023, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
07-02-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and nine months ended December 31, 2022. The advertisements as appeared today i.e. February 7, 2023 in Andhra Prabha (Telugu) and Business Standard. The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements This is for your information and record.
07-02-2023
Next Page
Close

Let's Open Free Demat Account